Exenatide
Exenatide (INN) (marketed as Byetta) is a medication (incretin mimetics) approved (Apr 2005) for the treatment of diabetes mellitus type 2. It is manufactured by Amylin Pharmaceuticals and Eli Lilly and Company.
Posted by admin / Under Exenatide
I have been a diagnosed diabetic for over 4 years now, since registering with my new GP at my wife's surgery. I have taken "Metformin" tablets with another called "Glycoside" .
Published on Thursday 29th of July 2010 09:05:01 AM
Posted by admin / Under Exenatide
Amylin Pharmaceuticals, Inc, Eli Lilly and Company and Alkermes, Inc announced that the US Food and Drug Administration (FDA) has classified the Bydureon (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.
Published on Thursday 29th of July 2010 09:05:01 AM
Posted by admin / Under Exenatide
The type 2 diabetes drug exenatide (Byetta) will have a revision to its label warning of altered kidney function, according to the FDA. LINK(S):
Published on Thursday 29th of July 2010 09:05:01 AM
Posted by admin / Under Exenatide
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for BYETTA(R) (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control
Published on Thursday 29th of July 2010 09:05:01 AM
Posted by admin / Under Exenatide
Diabetes is a chronic metabolic disease characterized by high glucose (sugar) levels in the blood. Insulin, a hormone produced by the pancreas, regulates the amount of glucose in the blood.
Published on Thursday 29th of July 2010 09:05:01 AM
Do not forget to check the lastest products and auctions related to Exenatide as well as our free videos and podcasts.
Spanish Armada: was defeated by the English, led by Sir Francis Drake (1588)
Share this!